博世健康股价上涨，Durect在收购协议后飙升

英为财情

2025/07/29

Investing.com -- 博世健康公司(Bausch Health Companies Inc.)(NYSE:BHC)股价上涨2.2%，而Durect Corporation(NASDAQ:DRRX)股价飙升263%，此前两家公司宣布达成最终协议，博世健康将收购Durect。此次收购包括Durect的新型治疗分子larsucosterol，该分子在治疗酒精性肝炎(AH)的二期临床试验中...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555057092"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555057092\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555057092?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-29 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555057092","market":"sh","top_or_hot":-1,"title":"博世健康股价上涨，Durect在收购协议后飙升","media":"英为财情","content":"<div>\n<p>Investing.com -- 博世健康公司(Bausch Health Companies Inc.)(NYSE:BHC)股价上涨2.2%，而Durect Corporation(NASDAQ:DRRX)股价飙升263%，此前两家公司宣布达成最终协议，博世健康将收购Durect。\n此次收购包括Durect的新型治疗分子larsucosterol，该分子在治疗酒精性肝炎(AH)的二期临床试验中...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2907858\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>博世健康股价上涨，Durect在收购协议后飙升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n博世健康股价上涨，Durect在收购协议后飙升\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-29 21:53 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/stock-market-news/article-93CH-2907858><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- 博世健康公司(Bausch Health Companies Inc.)(NYSE:BHC)股价上涨2.2%，而Durect Corporation(NASDAQ:DRRX)股价飙升263%，此前两家公司宣布达成最终协议，博世健康将收购Durect。\n此次收购包括Durect的新型治疗分子larsucosterol，该分子在治疗酒精性肝炎(AH)的二期临床试验中...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2907858\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EMA","symbol_name":"Emera Inc.","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2907858","article_id":"2555057092","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2907858","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555057092","pubTimestamp":1753797180,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com -- 博世健康公司股价上涨2.2%，而Durect Corporation股价飙升263%，此前两家公司宣布达成最终协议，博世健康将收购Durect。此次收购包括Durect的新型治疗分子larsucosterol，该分子在治疗酒精性肝炎的二期临床试验中显示出有希望的结果。根据协议条款，博世健康将以全现金交易方式支付每股1.75美元，在交易完成时代表约6300万美元的预付对价。收购价格较Durect截至2025年7月28日的30天成交量加权平均交易价格溢价约191%。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"EMA":"Emera Inc.","BK4557":"大麻股","BHC":"Bausch Health Companies Inc","BK4007":"制药","BK4081":"电力公用事业","DRRX":"Durect Corporation"},"translate_title":"Bosch Health Stock Rises, Durect Surges After Takeover Deal","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMA":1,"BHC":1,"DRRX":1},"content_text":"Investing.com -- 博世健康公司(Bausch Health Companies Inc.)(NYSE:BHC)股价上涨2.2%，而Durect Corporation(NASDAQ:DRRX)股价飙升263%，此前两家公司宣布达成最终协议，博世健康将收购Durect。\n此次收购包括Durect的新型治疗分子larsucosterol，该分子在治疗酒精性肝炎(AH)的二期临床试验中显示出有希望的结果。根据协议条款，博世健康将以全现金交易方式支付每股1.75美元，在交易完成时代表约6300万美元的预付对价。\n收购价格较Durect截至2025年7月28日的30天成交量加权平均交易价格溢价约191%。该交易还包括在特定截止日期前实现的两笔额外净销售里程碑付款，总计最高可达3.5亿美元。\n博世健康首席执行官Thomas J. Appio表示：\"这一公告是我们战略优先事项——创新的根本性进展。它展示了我们对肝病学的承诺，以及寻找新方法解决未满足医疗需求的决心。\"\n酒精性肝炎是一种危及生命的酒精相关肝病，2021年在美国约有16.4万例住院病例。目前，该病症尚无美国食品药品监督管理局(FDA)或欧洲药品管理局(EMA)批准的治疗方法。\n此次收购补充了博世健康正在全球范围内对肝硬化患者进行的利福昔明SSD的三期项目。目前正在计划一项注册性三期项目，评估larsucosterol治疗严重酒精性肝炎的效果，该项目将是一项随机、双盲、安慰剂对照的多中心研究，以90天生存率作为主要终点。\n该交易预计将在2025年第三季度完成，须满足惯例成交条件，包括Durect大多数流通股份被收购。\n\n本文由人工智能协助翻译。更多信息，请参见我们的使用条款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}